Chronic obstructive pulmonary disease and exacerbations: Patient insights from the global Hidden Depths of COPD survey

BMC Pulmonary Medicine

Klaus F Rabe⁴  Alan Kaplan³  Peter MA Calverley²  Neil Barnes¹ 

[1] Department of Respiratory Medicine, London Chest Hospital (Barts Health NHS Trust), Bonner Road, London E2 9JX, UK;Division of Infection and Immunity, Clinical Sciences Centre, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, UK;Canada and Bedford Park Family Medical Centre, University of Toronto, 17 Bedford Park Avenue, Richmond Hill, Ontario L4C 2N9, Canada;Department of Medicine, Germany and LungenClinic Grosshansdorf, members of the German Center for Lung Research, University Kiel, D-22927, Grosshansdorf, Germany

关键词: Survey;    Patient-reported;    Exacerbation;    COPD;   

Others  :  1109704
DOI  :  10.1186/1471-2466-13-54

 received in 2013-02-15, accepted in 2013-08-05,  发布年份 2013

【 摘 要 】

Background

Although chronic obstructive pulmonary disease (COPD) is a major global health burden there is a lack of patient awareness of disease severity, particularly in relation to exacerbations.

Methods

We conducted a global patient survey using an innovative, internet-based methodology to gain insight into patient perceptions of COPD and exacerbations in a real-world sample typical of today’s working-age COPD population.

Results

Two thousand patients with COPD (53%), chronic bronchitis (52%) and/or emphysema (22%) from 14 countries completed an online questionnaire developed by the authors. The Medical Research Council (MRC) breathlessness scale was used to delineate symptom severity. Over three quarters of patients (77%) had experienced an exacerbation, with 27% of MRC 1 and 2 patients and 52% of MRC 3, 4 and 5 patients requiring hospitalization as a result of an exacerbation. While a majority of MRC 1 and 2 patients (51%) reported being back to normal within a few days of an exacerbation, 23% of MRC 3, 4 and 5 patients took several weeks to return to normal and 6% never fully recovered. A high proportion of patients (39%) took a ‘wait and see’ approach to exacerbations.

Despite the high prevalence of exacerbations and their negative impact on quality of life, 73% of MRC 1 and 2 patients and 64% of MRC 3, 4 and 5 patients felt that they had control of their COPD. However, 77% of all patients were worried about their long-term health, and 38% of MRC 1 and 2 patients and 59% of MRC 3, 4 and 5 patients feared premature death due to COPD.

Conclusions

To reduce the adverse effects of COPD on patients’ quality of life and address their fears for the future, we need better patient education and improved prevention and treatment of exacerbations.

【 授权许可】

   
2013 Barnes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]WHO: World Health Statistics 2008. Available from: http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf webcite
• [2]European Respiratory Society/European Lung Foundation: European Lung White Book. European Respiratory: Society Journals Limited; 2003.
• [3]Vermeire P: The burden of chronic obstructive pulmonary disease. Respir Med 2002, 96(Suppl C):S3-S10.
• [4]From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2011. Available from: http://www.goldcopd.org/ webcite
• [5]Wouters EFM: Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003, 97(Suppl C):S3-S14.
• [6]Barr RG, Celli BR, Martinez FJ, Ries AL, Rennard SI, Reilly JJ, Sciurba FC, Thomashaw BM, Wise RA: Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med 2005, 118(12):1415-1424.
• [7]Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M: Patient's perception of exacerbations of COPD–the PERCEIVE study. Respir Med 2007, 101(3):453-460.
• [8]Fletcher MJ, Upton J, Taylor-Fishwick J, Barnes N, Buist AS, Hutton J, Jenkins C, Jones PW, Salapatas MD, Van der Molen T, Walsh JW, Walker S: COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Publ Health 2011, 11:612. BioMed Central Full Text
• [9]Barr RG, Celli BR, Mannino DM, Petty T, Rennard SI, Sciurba FC, Stoller JK, Thomashaw BM, Turino GM: Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009, 122(4):348-355.
• [10]Rennard S, Decramer M, Calverley PMA, Pride NB, Soriano JB, Vermeire PA, Vestbo J: Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002, 20(4):799-805.
• [11]Stenton C: The MRC, breathlessness scale. Occup Med 2008, 58(3):226-227.
• [12]Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA: Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1608-1613.
• [13]Eysenbach G: Improving the quality of web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES) Med. Internet Res 2004, 6(3):e34.
• [14]Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, on behalf of the BOLD Collaborative Research Group: International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 2007, 370(9589):741-750.
• [15]De Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P, for the European Community Respiratory Health Survey (ECRHS) Study Group: An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004, 59(2):120-125.
• [16]Agusti A, Calverely PMA, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J: Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010, 11:122-136.
• [17]Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE: Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010, 11:956-962.
• [18]Holgate ST, Price D, Valovirta E: Asthma out of control? A structured review of recent patient surveys. BMC Pulm Med 2006, 6(Suppl 1):S2. BioMed Central Full Text
• [19]Quint JK, Donaldson GC, Hurst JR, Goldring JJ, Seemungal TR, Wedzicha JA: Predictive accuracy of patient reported exacerbation frequency in chronic obstructive pulmonary disease. Eur Respir J 2011, 37(3):501-507.
• [20]Hurst JR, Donaldson GC, Quint JK, Goldring JJP, Baghai-Ravary R, Wedzicha JA: Temporal clustering of exacerbations in chronic Obstructive pulmonary disease. Am J Resp Crit Care 2009, 179(5):369-374.
• [21]Kessler R, Ståhl E, Vogelmeier C, Haughney J, Trudeau E, Löfdahl CG, Partridge MR: Patient understanding, detection and experience of COPD exacerbations. Chest 2006, 130(1):133-142.
• [22]Haughney J, Partridge MR, Vogelmeier C, Larsson T, Kessler R, Ståhl R, Brice R, Löfdahl CG: Exacerbations of COPD: quantifying the patient's perspective using discrete choice modelling. Eur Respir J 2005, 26:623-629.
• [23]Perera W, Hurst JR, Wilkinson TM, Sapsford RJ, Mullerova H, Donaldson GC, Wedzicha JA: Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007, 29:527-534.
• [24]Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA: Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 169(12):1298-1303.
• [25]Curtis JR: Palliative and end-of-life care for patients with severe COPD. Eur Respir J 2008, 32(3):796-803.
• [26]Gardiner C, Gott M, Payne S, Small N, Barnes S, Halpin D, Ruse C, Seamark D: Exploring the care needs of patients with advanced COPD: an overview of the literature. Respir Med 2010, 104(2):159-165.
• [27]Celli BR, MacNee W, ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946.
• [28]Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, on behalf of the GOLD Scientific Committee: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001, 163(5):1256-1276.